BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 28753755)

  • 1. Association between Lymph Node Counts and Oncological Outcomes in Lymph Node Positive Prostate Cancer.
    Mandel P; Kriegmair MC; Bogdan K; Boehm K; Budäus L; Graefen M; Huland H; Tilki D
    Eur Urol Focus; 2017 Apr; 3(2-3):248-255. PubMed ID: 28753755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era.
    Dorin RP; Lieskovsky G; Fairey AS; Cai J; Daneshmand S
    Urol Oncol; 2013 Nov; 31(8):1441-7. PubMed ID: 22516714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topography of lymph node metastases in prostate cancer patients undergoing radical prostatectomy and extended lymphadenectomy: results of a combined molecular and histopathologic mapping study.
    Heck MM; Retz M; Bandur M; Souchay M; Vitzthum E; Weirich G; Mollenhauer M; Schuster T; Autenrieth M; Kübler H; Maurer T; Thalgott M; Herkommer K; Gschwend JE; Nawroth R
    Eur Urol; 2014 Aug; 66(2):222-9. PubMed ID: 23465520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differing risk of cancer death among patients with lymph node metastasis after radical prostatectomy and pelvic lymph node dissection: identification of risk categories according to number of positive nodes and Gleason score.
    Schiavina R; Borghesi M; Brunocilla E; Manferrari F; Fiorentino M; Vagnoni V; Baccos A; Pultrone CV; Rocca GC; Rizzi S; Martorana G
    BJU Int; 2013 Jun; 111(8):1237-44. PubMed ID: 23331345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediate- and high-risk prostate cancer.
    Schiavina R; Manferrari F; Garofalo M; Bertaccini A; Vagnoni V; Guidi M; Borghesi M; Baccos A; Morselli-Labate AM; Concetti S; Martorana G
    BJU Int; 2011 Oct; 108(8):1262-8. PubMed ID: 21446934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy?
    Kluth LA; Xylinas E; Rieken M; Chun FK; Fajkovic H; Becker A; Karakiewicz PI; Passoni N; Herman M; Lotan Y; Seitz C; Schramek P; Remzi M; Loidl W; Guillonneau B; Rouprêt M; Briganti A; Scherr DS; Graefen M; Tewari AK; Shariat SF
    Urol Oncol; 2014 Jan; 32(1):47.e1-8. PubMed ID: 24055425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgeon-led prostate cancer lymph node staging: pathological outcomes stratified by robot-assisted dissection templates and patient selection.
    Altok M; Babaian K; Achim MF; Achim GC; Troncoso P; Matin SF; Chapin BF; Davis JW
    BJU Int; 2018 Jul; 122(1):66-75. PubMed ID: 29446205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term oncological outcomes in patients with limited nodal disease undergoing radical prostatectomy and pelvic lymph node dissection without adjuvant treatment.
    Mandel P; Rosenbaum C; Pompe RS; Steuber T; Salomon G; Chun FK; Graefen M; Huland H; Tilki D
    World J Urol; 2017 Dec; 35(12):1833-1839. PubMed ID: 28828530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
    Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
    BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Pelvic Lymph Node Dissection During Radical Prostatectomy in Patients With Gleason 6 Intermediate-risk Prostate Cancer.
    Mandel P; Kriegmair MC; Veleva V; Salomon G; Graefen M; Huland H; Tilki D
    Urology; 2016 Jul; 93():141-6. PubMed ID: 26968487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Robotic-assisted pelvic lymph node dissection for prostate cancer: frequency of nodal metastases and oncological outcomes.
    Ledezma RA; Negron E; Razmaria AA; Dangle P; Eggener SE; Shalhav AL; Zagaja GP
    World J Urol; 2015 Nov; 33(11):1689-94. PubMed ID: 25701128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis of patients with pelvic lymph node (LN) metastasis after radical prostatectomy: value of extranodal extension and size of the largest LN metastasis.
    Passoni NM; Fajkovic H; Xylinas E; Kluth L; Seitz C; Robinson BD; Rouprêt M; Chun FK; Lotan Y; Roehrborn CG; Crivelli JJ; Karakiewicz PI; Scherr DS; Rink M; Graefen M; Schramek P; Briganti A; Montorsi F; Tewari A; Shariat SF
    BJU Int; 2014 Oct; 114(4):503-10. PubMed ID: 24053552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of pelvic lymph node dissection and node-positive disease on biochemical recurrence, secondary treatment, and survival after radical prostatectomy in men with prostate cancer.
    Washington SL; Cowan JE; Herlemann A; Zuniga KB; Masic S; Nguyen HG; Carroll PR
    Prostate; 2021 Feb; 81(2):102-108. PubMed ID: 33075151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review.
    Fossati N; Willemse PM; Van den Broeck T; van den Bergh RCN; Yuan CY; Briers E; Bellmunt J; Bolla M; Cornford P; De Santis M; MacPepple E; Henry AM; Mason MD; Matveev VB; van der Poel HG; van der Kwast TH; Rouvière O; Schoots IG; Wiegel T; Lam TB; Mottet N; Joniau S
    Eur Urol; 2017 Jul; 72(1):84-109. PubMed ID: 28126351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extranodal extension is a powerful prognostic factor in bladder cancer patients with lymph node metastasis.
    Fajkovic H; Cha EK; Jeldres C; Robinson BD; Rink M; Xylinas E; Chromecki TF; Breinl E; Svatek RS; Donner G; Tagawa ST; Tilki D; Bastian PJ; Karakiewicz PI; Volkmer BG; Novara G; Joual A; Faison T; Sonpavde G; Daneshmand S; Lotan Y; Scherr DS; Shariat SF
    Eur Urol; 2013 Nov; 64(5):837-45. PubMed ID: 22877503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indication for and extension of pelvic lymph node dissection during robot-assisted radical prostatectomy: an analysis of five European institutions.
    Suardi N; Larcher A; Haese A; Ficarra V; Govorov A; Buffi NM; Walz J; Rocco B; Borghesi M; Steuber T; Pini G; Briganti A; Mottrie AM; Guazzoni G; Montorsi F; Pushkar D; Van Der Poel H;
    Eur Urol; 2014 Oct; 66(4):635-43. PubMed ID: 24411992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer.
    Abdollah F; Gandaglia G; Suardi N; Capitanio U; Salonia A; Nini A; Moschini M; Sun M; Karakiewicz PI; Shariat SF; Montorsi F; Briganti A
    Eur Urol; 2015 Feb; 67(2):212-9. PubMed ID: 24882672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-volume lymph node involvement and biochemical recurrence after robot-assisted radical prostatectomy with extended lymph node dissection in prostate cancer.
    Morizane S; Honda M; Shimizu R; Teraoka S; Nishikawa R; Tsounapi P; Kimura Y; Iwamoto H; Hikita K; Takenaka A
    Int J Clin Oncol; 2020 Jul; 25(7):1398-1404. PubMed ID: 32333202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.